Physician profile
Devinn Wolfe
NPI 1497206908
$13,752.99
in general payments reported to CMS, 2019-2025
48 companies · $3,113 in 2025
The $3,113 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,514 · 2022: $2,744 · 2023: $2,664 · 2024: $2,718 · 2025: $3,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,447 · Education: $48.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,446.52 |
| Education | $48.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,433.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,877.06 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,820.40 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $1,055.92 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.83 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $664.19 | 2021-2025 | Korlym |
| Amgen INC. | $538.56 | 2021-2025 | Evenity, Tepezza, Prolia |
| Insulet Corporation | $475.95 | 2021-2025 | Omnipod |
| Abbvie INC. | $393.79 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $379.32 | 2021-2025 | |
| Pfizer INC. | $308.27 | 2021-2025 | |
| Dexcom, INC. | $253.95 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $250.34 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $242.71 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $207.05 | 2021-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $165.03 | 2021-2025 | Minimed 780g |
| Horizon Therapeutics Plc | $164.39 | 2022-2023 | |
| Sequel Med Tech, LLC | $159.12 | 2025 | Twiist |
| Amryt Pharma Holdings Ltd | $154.73 | 2022-2023 | Mycapssa |
| Lifescan, INC. | $131.02 | 2021-2022 | |
| Chiesi USA, INC. | $116.85 | 2024-2025 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $114.05 | 2023-2025 | Yorvipath |
| Beta Bionics, INC. | $101.25 | 2024 | Ilet Bionic Pancreas |
| Ibsa Pharma INC. | $87.14 | 2023-2025 | Tirosint, Licart, Flector |
| Esperion Therapeutics, INC. | $71.64 | 2021 | |
| Radius Health, INC. | $68.22 | 2021-2025 | Tymlos |
| Antares Pharma, INC. | $64.94 | 2024-2025 | Xyosted |
| Amneal Pharmaceuticals LLC | $56.00 | 2021-2023 | Unithroid |
| Ascensia Diabetes Care US INC. | $54.53 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $48.13 | 2023-2025 | Rayaldee |
| Verity Pharmaceuticals INC. | $46.73 | 2025 | Tlando |
| Tandem Diabetes Care, INC. | $45.18 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ipsen Biopharmaceuticals, INC | $43.52 | 2022 | |
| Aimmune Therapeutics, INC. | $42.88 | 2024 | |
| Novartis Pharmaceuticals Corporation | $40.80 | 2021-2022 | |
| Mannkind Corporation | $35.10 | 2021-2024 | |
| Eisai INC. | $34.74 | 2022 | |
| Cequr Corporation | $34.52 | 2024 | Cequr Simplicity |
| Grt US Holding, INC. | $31.92 | 2021-2022 | |
| Madrigal Pharmaceuticals | $28.96 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $23.42 | 2024 | Qutenza |
| Almatica Pharma LLC | $23.03 | 2024 | Teriparatide |
| Amphastar Pharmaceuticals, INC. | $19.85 | 2025 | |
| Hologic Sales and Service, LLC | $19.65 | 2025 | Aptima |
| Alexion Pharmaceuticals, INC. | $19.64 | 2025 | Strensiq |
| Acella Pharmaceuticals, LLC | $19.52 | 2025 | NP Thyroid 60 |
| Kyowa Kirin, INC. | $19.15 | 2023 | |
| Currax Pharmaceuticals LLC | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devinn Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.